Next Article in Journal
Agouti-Signaling Protein and Melanocortin-1-Receptor Mutations Associated with Coat Color Phenotypes in Fallow Deer (Dama dama)
Previous Article in Journal
The Phenotypic Spectrum of 16p11.2 Recurrent Chromosomal Rearrangements
Previous Article in Special Issue
Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 15
Issue 8
10.3390/genes15081054
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia

by
Guillermina Chavaro-Francisco
1,2,
Araceli Hernández-Zavala
1,
Camila E. Bravo-Cidro
2,3,
Sandybel Rios-Rodriguez
2,3,
Mabel Muciño-Sánchez
2,4,
Marisol López-López
3,
Xóchitl H. Castro-Martínez
5,
Irma Olarte-Carrillo
6,
Anel Garcia-Laguna
6,
Gilberto Barranco-Lampón
6,
Adrián De la Cruz-Rosas
6,
Adolfo Martínez-Tovar
6 and
Emilio J. Córdova
2,*
1
Section of Research and Postgraduate Studies, Superior School of Medicine, National Institute Polytechique, Mexico City 11340, Mexico
2
Oncogenomics Consortium Laboratory, Clinic Research Department, National Institute of Genomic Medicine, Mexico City 14610, Mexico
3
Department of Biological Systems, Metropolitan Autonomous University, Campus Xochimilco, Mexico City 04960, Mexico
4
School of Biology, Metropolitan Autonomous University, Campus Xochimilco, Mexico City 04960, Mexico
5
Genomics of Psychiatric and Neurogenerative Diseases Laboratory, National Institute of Genomic Medicine, Mexico City 14610, Mexico
6
Molecular Biology Laboratory, Service of Hematology, Hospital General de Mexico, “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico
*
Author to whom correspondence should be addressed.
Genes 2024, 15(8), 1054; https://doi.org/10.3390/genes15081054
Submission received: 2 July 2024 / Revised: 6 August 2024 / Accepted: 8 August 2024 / Published: 10 August 2024
(This article belongs to the Special Issue Cancer Risk and Gene Variations)
Versions Notes

Abstract

:
Current therapy in chronic myeloid leukemia (CML) has improved patient life expectancy close to that of healthy individuals. However, molecular alterations other than BCR::ABL1 fusion gene in CML are barely known. MicroRNAs are important regulators of gene expression, and variants in some of the components of microRNA biosynthesis pathways have been associated with genetic susceptibility to different types of cancer. Thus, the aim of this study was to evaluate the association of variants located in genes involved in the biogenesis of microRNAs with susceptibility to CML. Fifteen variants in eight genes involved in the biogenesis of miRNAs were genotyped in 296 individuals with CML and 485 healthy participants using TaqMan probes. The association of gene variants with CML and clinical variables was evaluated by a Chi-square test, and odds ratios and 95% confidence intervals were estimated by logistic regression. The variant rs13078 in DICER1 was significantly higher among CML individuals than in healthy participants. In addition, the variants rs7813 and rs2740349 were significantly associated with worse prognosis, according to their Hasford scores, whereas the rs2740349 variant was also associated with a later age at diagnosis. These findings suggest that variants in components of the microRNA biogenesis pathway could be involved in CML genetic risk.

1. Introduction

Chronic myeloid leukemia (CML) is a myeloproliferative malignant disease characterized by the presence of an aberrantly short chromosome 22, named the Philadelphia chromosome. This altered chromosome is the product of reciprocal translocation t(9;22)(q34;q31) and results in the fusion of the BCR gene in chromosome 22 with the ABL1 gene located in chromosome 9 [1]. The BCR::ABL1 fusion gene encodes a chimeric protein with the exacerbated activity of tyrosine kinase, which is capable of activating different intracellular signaling pathways, including RAS-MAPK, JAK-STAT, and SRC [2].
The characterization of the BCR::ABL1 fusion gene as the main molecular alteration underlying CML development allowed the design of the first successful target therapy for malignant diseases. This therapy was based on the use of Imatinib, a highly specific tyrosine kinase inhibitor (TKI), which was significantly more efficient than Interferon, the conventional therapy used in the past in the treatment of CML [3]. At present, five other TKIs have been approved by the FDA for CML therapy, including nilotinib, dasatinib, bosutinib (second generation), ponatinib (third generation), and asciminib (fourth generation) [4]. Currently, the use of TKIs as the first-line therapy in CML has significantly increased 10-year survival rates from 20% to 85% [4]. Although a small group of CML patients (10–15%) show resistance or intolerance to TKIs, most CML patients exhibit life expectancies similar to those found in healthy individuals [5].
In contrast to the great advancement in the treatment of CML, worldwide incidence of this disease has remained unchanged, and as a consequence of the success of TKI therapy, its prevalence has significantly increased in the last few years. In this sense, it was estimated that in 2017, about 15 million people were living with CML around the world [6]. Risk factors associated with CML, including genetic factors, are not widely known, with high exposure to radiation and benzene as the only recognized factors related to CML development [7]. The identification of the genetic factors associated with increased CML risk could help in the establishment of public health strategies that allow the prevention of this disease with a consequent reduction in its prevalence.
MicroRNAs (miRNAs) are short, non-coding RNAs of 19–22 nucleotides long that post-transcriptionally regulate gene expression by directly binding to protein-coding transcripts [8]. MiRNAs interact with their target transcripts through base pair complementarity binding between a short sequence located at the miRNA 5′ end, named the seed region, and a canonical sequence situated in the 3′ untranslated region (3′ UTR) of the target transcript. Since the seed regions in miRNAs are very short sequences, each individual miRNA can regulate different transcripts, and in the same sense, an individual transcript can be regulated by different miRNAs [9,10]. At present, more than 2600 mature sequences of miRNAs have been deposited in an international database reservoir called miRBase [10], and it has been estimated that about 30% of coding genes might be regulated by miRNAs [11].
MiRNAs regulate several cellular processes, including proliferation, survival, and differentiation [12]. Accordingly, alterations in the expression of miRNAs are a common event in different types of cancers. For instance, the up-regulation of miR-130b-5p and miR-222-3p has been reported in breast cancer [13], whereas the down-regulation of miR-148a and miR-152 has been observed in gastric [14,15] and bladder cancers [16]. In addition, genetic studies have revealed that the aberrant expression of miR-126 plays a critical role in the leukemogenesis and progression of acute myeloid leukemia [17]. Particularly in CML, miR-125a-3p and miR-320b are differentially expressed in CML patients [18]. In an independent study, the down-regulation of miR-342-5p expression was found to be associated with CML progression [19]. Taken together, these findings indicate the importance of miRNA regulation in different types of cancers, including leukemia.
The biogenesis of miRNAs is a highly regulated multi-step process, starting with its transcription by RNA polymerase II as long hairpin structures called primary miRNAs (pri-miRNAs). Since miRNAs can be transcribed as monocystronic (one gene) or polycistronic (multiple genes) transcripts, the sizes of pri-miRNAs are highly diverse. Later, pri-miRNAs are cleaved into precursor miRNAs (pre-miRNAs) of ~65–70 nucleotides long by a type III ribonuclease named DROSHA in complexes with DGCR8 proteins. Then, pre-miRNAs are transported into the cytoplasm by the Exportin-5 (XP05)–RAN complex and further processed into ~22 nucleotide mature duplex RNA molecules, by another type III ribonuclease called DICER1 in complexes with the TRBP protein. This mature duplex miRNA are composed of a passenger and a guide strand. The passenger miRNA strand is usually degraded, whereas the guide miRNA strand is loaded into the RNA-induced silencing complex (RISC) by the proteins AGO1-4 and GEMIN3-4 [20].
Recent studies have demonstrated the importance of gene variants in components of the biosynthesis process of miRNAs as risk factors for different human diseases. For instance, variants rs7813 in GEMIN4 and rs636832 in AGO1 have been associated with an increased risk of the multiple sclerosis variant [21], whereas variant rs13078 in DICER1 has been associated with a decreased risk of type 2 diabetes mellitus [22]. In addition, the variants rs197388 in GEMIN3 and rs3744741 in GEMIN4 have been associated with an increased risk of depression [23]. In the case of malignant diseases, the variants rs7157322 and rs3742330 in the DICER1 gene have been associated with gastric adenocarcinoma and papillary thyroid cancer, respectively [24,25]. Similarly, variants rs3742330 in DICER1, rs11077 in XPO5, and rs10719 in DROSHA are associated with colorectal cancer risk [26]. Importantly, functional assays have demonstrated that variant rs10719, located in the 3’ untranslated region of DROSHA, decreases the binding of hsa-miR-27b with the consequent elevation of DROSHA transcripts [27].
Currently, no studies about the participation of variants in miRNA biogenesis and CML development have been performed. Since alterations in the expression of miRNAs are found in CML, variants in genes involved in the biogenesis of miRNAs could be associated with this disease. Thus, the aim of the present study was to analyze the association of gene variants in components of the miRNA machinery pathway and the development of CML.

2. Material and Methods

2.1. Study Population

Our sample population was composed of a total of 781 unrelated subjects, comprising 296 individuals previously diagnosed with CML and 485 unrelated healthy persons. Case and control subjects were recruited from tertiary hospitals in Mexico City. The case group was composed of 170 (57%) males and 126 (43%) females, whereas the control group comprised 271 (56%) males and 214 (44%) females. The median ages in the case and control groups were 45 ± 14.7 and 48 ± 7.4, respectively. CML was initially diagnosed by a hematological test and then confirmed through the detection of translocation t(9;22)(q34;q11) by conventional cytogenetics, or the detection of BCR::ABL1 transcripts by qPCR. All participants with CML were of recent diagnoses and all of them were in the chronic phase of the disease.
This study was conducted in accordance with the Declaration of Helsinki and approved by the Research and Ethics Committees of the National Institute of Genomic Medicine (Registry number 13/2019/1). All participants signed a written informed consent form.

2.2. Gene Variant Genotyping

Genomic DNA was extracted from 10 mL of circulating blood samples using the Puregene blood kit following manufacturer instructions (Qiagen, Hilden, Germany). Sample genotyping was performed using commercial TaqMan probes as follows: rs2293939 (C_1707002_10), rs4961280 (C_11609859_10), rs720012 (C_2255497_30), rs3742330 (C_27475447_10), rs13078 (C_7504801_10), rs10719 (C_7761648_10), rs6877842 (C_1153852_10), rs197388 (C_32363724_30), rs197414 (C_923336_10), rs7813 (C_2988802_40), rs2740349 (C_2988801_1), rs4968104 (C_22274226_10), rs9611280 (C_29619916_10), rs11077 (C_3109165_1), and rs34324334 (C_25933077_10) (Applied Biosystems, Foster City, CA, USA). PCR amplification for allelic discrimination was carried out in a QuantStudio 3 real-time PCR and analyzed in the Design & Analysis Software V. 2.8.0 (Applied Biosystem, Foster City, CA, USA). The genotyping call rate exceeded 95%. Approximately 20% of the samples were randomly genotyped twice, with concordance above 98%.

2.3. Statistical Analysis

Deviation from the Hardy–Weinberg equilibrium was determined by a Chi-square test. To evaluate the association of variants in components of the miRNA biogenesis process with CML and clinical variables, Chi-square and Fisher’s tests were performed. Additionally, odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a logistic regression model. Linear regression was used to evaluate the effect of gene variants on age at CML diagnosis (β value). Both methods were adjusted by age and sex. All statistical analyses were performed with the PLINK software 1.9 [28]. A p-value less than 0.05 was considered as the threshold of statistical significance.

3. Results

3.1. Characteristics of the Study Population

The demographic and clinical characteristics of CML patients and healthy individuals are shown in Table 1. From the 296 individuals diagnosed with CML, clinical data for Sokal and Hasford scores were obtained from 118 participants, whereas clinical data for EUTOS scores could only be obtained from 97 participants. Based on Sokal scores, 44% of patients were classified as high risk, 29% as intermediate risk, and 27% as low risk. Regarding Hasford scores, 41% of patients were classified as high risk, 30% as intermediate risk, and 29% as low risk, respectively. According to EUTOS scores, 52% were classified as high risk and 48% as low risk (Table 1).

3.2. Gene Variants in Components of miRNA Biosynthesis Pathway and CML

After genotyping the 15 studied variants in the case and control groups, the minor allele frequency of rs197414 in GEMIN3 and rs4968104 in GEMIN4 significantly deviated from the Hardy–Weinberg equilibrium (p < 0.05). Thus, both variants were excluded from further analysis. The rest of the variants showed no deviation from the Hardy–Weinberg equilibrium. In the association study, the frequency of the minor allele of rs13078 in DICER1 was significantly higher in individuals affected with CML in comparison to healthy subjects (0.09 vs. 0.06; OR = 1.64, 95% CI [1.105–2.421], p = 0.013; Table 2). Moreover, the number of participants carrying the minor homozygote genotype of this variant was significantly higher among the cases compared to the controls (0.034 vs. 0.002; OR = 15.06, 95% CI [2.824–373.6]; Table 3). It is worth noting that no significant differences were observed in the number of individuals carrying the heterozygote genotype of this variant among the cases and controls, suggesting a recessive effect. The allele and genotype frequencies of the rest of the studied variants showed no significant differences between the cases and controls (Table 2 and Table 3).

3.3. Association of Variants in Components of miRNA Biogenesis with Prognostic Scores and Age at Diagnosis in CML

To analyze the participation of SNVs in miRNA biogenesis pathways with CML progression, the association of the studied variants with the prognostic scores of EUTOS, Sokal, and Hasford was evaluated. For comparison purposes, participants with low and middle risk in the Sokal and Hasford scores were grouped together with participants classified as low risk in the EUTOS scores. For the comparison of participants with high risk in the three prognostic scores against individuals with low risk for EUTOS and low and middle risk in the Sokal and Hasford scores, the frequency of minor alleles of the variants rs7813 and rs2740349 in GEMIN4 was higher in the high-risk group than in the low- and middle-risk group (Sokal: 0.36 vs. 0.26 and 0.25 vs. 017; Hasford: 0.39 vs. 0.24 and 0.27 vs. 0.14; and EUTOS: 0.35 vs. 0.26 0.23 vs. 0.17, respectively). However, only in the case of the Hasford score was this difference statistically significant for both variants (rs7813: OR = 1.96, p = 0.019 and rs2740349: OR = 2.23, p = 0.015, respectively). None of the other studied variants showed any association with CML prognostic scores (Table 4).
The impact of variants in miRNA biosynthesis on age at diagnosis was also evaluated. In this analysis, CML individuals carrying the variant allele of rs2740349 in GEMIN4 showed a significantly later age at diagnosis than CML participants with the wild-type allele (~5 years, p = 0.003; Table 5). The variant rs7813, also present in GEMIN4, showed a tendency to associate with a later age at diagnosis (~3 years, p = 0.059; Table 5). None of the other variants showed any association with age at diagnosis.

4. Discussion

MiRNAs are important regulators in different cellular processes, including proliferation, apoptosis, and cellular differentiation. Accordingly, alterations in the expression of miRNAs are frequently found in a variety of human illnesses, including cancer, diabetes, and cardiovascular diseases [12,13,14,15,16]. Importantly, recent studies have demonstrated that genetic variants in components of miRNA biogenesis pathways could be involved in the development of several types of cancer and metabolic diseases [21,22,23,24,25].
In this study, the association of 15 SNVs in eight genes involved in the biosynthesis process of miRNAs with CML susceptibility was evaluated. As important observations, the frequency of the minor allele and the minor homozygote genotype of the variant rs13078 in DICER1 was significantly higher among CML individuals than in healthy participants. Additionally, the frequency of the minor alleles of GEMIN4 variants rs7813 and rs2740349 was higher in the group of CML patients with high risk in comparison to the intermediate- and low-risk group according to their Hasford, EUTOS, and Sokal scores; however, this difference was significant only in the case of the Hasford score. Considering that all CML participants included in this study were in the chronic phase of the disease, this finding indicates that variants rs7813 and rs2740349 could be associated with a worse prognosis. Finally, the presence of the variant allele of rs2740349 was significantly associated with a later age at diagnosis of CML in comparison to noncarriers, whereas the variant rs7813 showed only a small association.
The DICER1 gene encodes a protein of approximately 218 kDa with the activity of type III ribonuclease involved in the regulation of several small non-coding RNA pathways [29]. Alterations in the expression of DICER1 have been found in different types of cancer such as breast carcinoma, hepatocellular carcinoma, and lung cancer [30,31,32]. Moreover, germline mutations in the DICER1 coding region, which affects protein activity, have been related to a rare autosomal dominant genetic disorder named DICER syndrome [33,34]. This syndrome influences different benign and malignant tumors characterized by DICER1 loss of function [35,36]. Moreover, in papillary thyroid cancer samples, pathogenic somatic variants in the DICER1 gene are associated with a reduction in the abundance of 5p-derived miRNAs [37]. In this sense, common variants in DICER1, such as rs13078, rs105703, and rs3742330, have been associated with a variety of human illnesses, including cancer, diabetes, cardiovascular, autoimmune, and neurodegenerative diseases [22,38,39,40,41].
The rs13078 variant is located at the 3′UTR region of the gene, and it has been previously associated with decreased risk of type-2 diabetes [22] and increased risk of gestational hypertension, idiopathic male infertility, hepatocellular carcinoma, and larynx cancer [42,43,44,45]. A previous report demonstrated the direct binding of miR-892a to the 3′UTR of DICER1 transcripts in a human laryngeal-cancer-derived cell line with a consequent reduction in DICER1 protein levels [46]. In this sense, variant rs13078 could modify the interaction of different miRNAs or RNA-binding proteins with DICER1 transcripts, affecting the abundance of the protein and potentially affecting the global expression of miRNAs.
GEMIN4 is a protein of approximately 120 kD, which is part of a multiprotein complex involved not only in miRNA biogenesis but also in the assembly and organization of the small nuclear ribonucleoproteins needed for mRNA splicing [47]. Recent studies have reported the association of germinal pathogenic variants in GEMIN4 with an inherited neurodevelopmental disorder characterized by microcephaly, cataracts, and renal abnormalities [48,49]. An independent study also demonstrated the association of germinal variants with pediatric cataract syndrome [50]. Moreover, common variants in GEMIN4, such as rs7813, rs3744741, rs910924, and rs595961, have been associated with a variety of human diseases, including multiple sclerosis, depression, and cancer in different organs such as the stomach, lungs, and kidneys, among others [21,23,51,52,53].
The variants rs7813 and rs2740349 are missense variants (Arg1033Cys and Asp929Tyr, respectively). Although the variant rs2740349 has not been associated with any illnesses, previous studies have reported the association of rs7813 with several diseases, including multiple sclerosis, tuberculosis, gastric cancer, and lung cancer, among others [21,51,52,53,54,55]. Similar to our findings, the rs7813 variant was reported to be associated with the prognosis of esophageal squamous cell carcinoma [56].
This is the first study showing the association of variants in components of miRNA biogenesis pathways with CML and the progression of the disease. An important limitation of this study is the small number of CML individuals with available data for prognostic scores. However, our findings are in line with previous studies indicating the relevance of gene variants in miRNA biogenesis pathways in different types of malignant diseases. Further studies evaluating the impact of variants in miRNA biogenesis pathways on the abundance of miRNAs associated with CML are warranted.

Author Contributions

Conceptualization, E.J.C.; sample collection, I.O.-C., A.G.-L., G.B.-L., A.D.l.C.-R. and A.M.-T.; methodology, G.C.-F., C.E.B.-C., S.R.-R. and M.M.-S.; formal analysis G.C.-F.; writing—original draft preparation, X.H.C.-M. and G.C.-F.; writing—review and editing, A.H.-Z., M.L.-L. and E.J.C.; supervision, E.J.C.; project administration E.J.C.; and funding acquisition, A.H.-Z. and E.J.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Institute of Genomic Medicine [Grant No. 13/2019/I] and the Consejo Nacional de Humanidades, Ciencia y Tecnología [Grant No.: FOSISS A3-S-45155]. G.C.-F. funding was provided by the Consejo Nacional de Humanidades, Ciencia y Tecnología fellowship No. CVU:1002577.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Research and Ethics Committees of the National Institute of Genomic Medicine (Registry number 13/2019/1 and date of approval 4 June 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement

The original contributions presented in this study are included in the article, further inquiries can be directed to the corresponding author.

Acknowledgments

We thank Omar Tecozautla-Romero, Julio Cesar Canseco-Mendez and Haydee Miranda-Ortiz for their technical assistance.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Osman, A.E.; Deininger, M.W. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021, 49, 100825. [Google Scholar] [CrossRef]
  2. Baccarani, M.; Rosti, G.; Soverini, S. Chronic myeloid leukemia: The concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia 2019, 33, 2358–2364. [Google Scholar] [CrossRef]
  3. O’Brien, S.G.; Guilhot, F.; Larson, R.A.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.J.; Fischer, T.; Hochhaus, A.; Hughes, T.; et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N. Engl. J. Med. 2003, 348, 994–1004. [Google Scholar] [CrossRef]
  4. Wang, Y.; Liang, Z.-J.; Gale, R.P.; Liao, H.-Z.; Ma, J.; Gong, T.-J.; Shao, Y.-Q.; Liang, Y.; Wang, Y.; Liang, Z.-J.; et al. Chronic myeloid leukaemia: Biology and therapy. Blood Rev. 2024, 65, 101196. [Google Scholar] [CrossRef]
  5. Bower, H.; Björkholm, M.; Dickman, P.W.; Höglund, M.; Lambert, P.C.; Andersson, T.M.-L. Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J. Clin. Oncol. 2016, 34, 2851–2857. [Google Scholar] [CrossRef]
  6. Lin, Q.; Mao, L.; Shao, L.; Zhu, L.; Han, Q.; Zhu, H.; Jin, J.; You, L. Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Front. Oncol. 2020, 10, 580759. [Google Scholar] [CrossRef]
  7. Kabat, G.C.; Wu, J.W.; Moore, S.C.; Morton, L.M.; Park, Y.; Hollenbeck, A.R.; Rohan, T.E. Lifestyle and Dietary Factors in Relation to Risk of Chronic Myeloid Leukemia in the NIH-AARP Diet and Health Study. Cancer Epidemiol. Biomark. Prev. 2013, 22, 848–854. [Google Scholar] [CrossRef]
  8. Mohr, A.M.; Mott, J.L. Overview of MicroRNA Biology. Semin. Liver Dis. 2015, 35, 003–011. [Google Scholar] [CrossRef]
  9. Fu, Z.; Wang, L.; Li, S.; Chen, F.; Au-Yeung, K.K.-W.; Shi, C. MicroRNA as an Important Target for Anticancer Drug Development. Front. Pharmacol. 2021, 12, 736323. [Google Scholar] [CrossRef]
  10. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019, 47, D155–D162. [Google Scholar] [CrossRef]
  11. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets. Cell 2005, 120, 15–20. [Google Scholar] [CrossRef]
  12. Mens, M.M.J.; Ghanbari, M. Cell Cycle Regulation of Stem Cells by MicroRNAs. Stem Cell Rev. Rep. 2018, 14, 309–322. [Google Scholar] [CrossRef]
  13. Wang, Y.; Yin, W.; Lin, Y.; Yin, K.; Zhou, L.; Du, Y.; Yan, T.; Lu, J. Downregulated circulating microRNAs after surgery: Potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discov. 2018, 4, 87. [Google Scholar] [CrossRef]
  14. Chen, Y.; Song, Y.; Wang, Z.; Yue, Z.; Xu, H.; Xing, C.; Liu, Z. Altered Expression of MiR-148a and MiR-152 in Gastrointestinal Cancers and Its Clinical Significance. J. Gastrointest. Surg. 2010, 14, 1170–1179. [Google Scholar] [CrossRef]
  15. Guo, S.-L.; Peng, Z.; Yang, X.; Fan, K.-J.; Ye, H.; Li, Z.-H.; Wang, Y.; Xu, X.-L.; Li, J.; Wang, Y.-L.; et al. miR-148a Promoted Cell Proliferation by Targeting p27 in Gastric Cancer Cells. Int. J. Biol. Sci. 2011, 7, 567–574. [Google Scholar] [CrossRef]
  16. Wang, X.; Liang, Z.; Xu, X.; Li, J.; Zhu, Y.; Meng, S.; Li, S.; Wang, S.; Xie, B.; Ji, A.; et al. miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis. 2016, 7, e2503. [Google Scholar] [CrossRef]
  17. Zhang, L.; Nguyen, L.X.T.; Chen, Y.-C.; Wu, D.; Cook, G.J.; Hoang, D.H.; Brewer, C.J.; He, X.; Dong, H.; Li, S.; et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat. Commun. 2021, 12, 6154. [Google Scholar] [CrossRef]
  18. Martins, J.R.B.; Moraes, L.N.; Cury, S.S.; Capannacci, J.; Carvalho, R.F.; Nogueira, C.R.; Hokama, N.K.; Hokama, P.O.M. MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. Int. J. Mol. Sci. 2021, 22, 10216. [Google Scholar] [CrossRef]
  19. Wu, Y.-Y.; Lai, H.-F.; Huang, T.-C.; Chen, Y.-G.; Ye, R.-H.; Chang, P.-Y.; Lai, S.-W.; Chen, Y.-C.; Lee, C.-H.; Liu, W.-N.; et al. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance. Cell Death Dis. 2021, 12, 908. [Google Scholar] [CrossRef]
  20. O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018, 9, 402. [Google Scholar] [CrossRef]
  21. Sung, H.; Yang, H.H.; Zhang, H.; Yang, Q.; Hu, N.; Tang, Z.-Z.; Su, H.; Wang, L.; Wang, C.; Ding, T.; et al. Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers. Leuk. Res. 2015, 44, 1341–1352. [Google Scholar] [CrossRef] [PubMed]
  22. Mohammadpour-Gharehbagh, A.; Heidari, Z.; Eskandari, M.; Aryan, A.; Salimi, S. Association between Genetic Polymorphisms in microRNA Machinery Genes and Risk of Papillary Thyroid Carcinoma. Pathol. Oncol. Res. 2019, 26, 1235–1241. [Google Scholar] [CrossRef] [PubMed]
  23. Basak, J.; Piotrzkowska, D.; Majsterek, I.; Kucharska, E. Relationship between the Occurrence of Genetic Variants of Single Nucleotide Polymorphism in microRNA Processing Genes and the Risk of Developing Multiple Sclerosis. Biomedicines 2022, 10, 3124. [Google Scholar] [CrossRef] [PubMed]
  24. Wen, Z.; Zou, X.; Xie, X.; Zheng, S.; Chen, X.; Zhu, K.; Dong, S.; Liang, J.; Huang, X.; Liu, D.; et al. Association of Polymorphisms in miRNA Processing Genes with Type 2 Diabetes Mellitus and Its Vascular Complications in a Southern Chinese Population. Front. Endocrinol. 2019, 10, 461. [Google Scholar] [CrossRef] [PubMed]
  25. Kowalczyk, M.; Kowalczyk, E.; Gogolewska, M.; Skrzypek, M.; Talarowska, M.; Majsterek, I.; Poplawski, T.; Kwiatkowski, P.; Sienkiewicz, M. Association of polymorphic variants in GEMIN genes with the risk of depression in a Polish population. PeerJ 2022, 10, e14317. [Google Scholar] [CrossRef] [PubMed]
  26. Cho, S.H.; Ko, J.J.; Kim, J.O.; Jeon, Y.J.; Yoo, J.K.; Oh, J.; Oh, D.; Kim, J.W.; Kim, N.K. 3′-UTR Polymorphisms in the MiRNA Machinery Genes DROSHA, DICER1, RAN, and XPO5 Are Associated with Colorectal Cancer Risk in a Korean Population. PLoS ONE 2015, 10, e0131125. [Google Scholar] [CrossRef] [PubMed]
  27. Yuan, L.; Chu, H.; Wang, M.; Gu, X.; Shi, D.; Ma, L.; Zhong, D.; Du, M.; Li, P.; Tong, N.; et al. Genetic Variation in DROSHA 3′UTR Regulated by hsa-miR-27b Is Associated with Bladder Cancer Risk. PLoS ONE 2013, 8, e81524. [Google Scholar] [CrossRef] [PubMed]
  28. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am. J. Hum. Genet. 2007, 81, 559–575. [Google Scholar] [CrossRef] [PubMed]
  29. Ji, X. The mechanism of RNase III action: How dicer dices. Curr. Top. Microbiol. Immunol. 2008, 320, 99–116. [Google Scholar]
  30. Grelier, G.; Voirin, N.; Ay, A.-S.; Cox, D.G.; Chabaud, S.; Treilleux, I.; Léon-Goddard, S.; Rimokh, R.; Mikaelian, I.; Venoux, C.; et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br. J. Cancer 2009, 101, 673–683. [Google Scholar] [CrossRef]
  31. Wu, J.-F.; Shen, W.; Liu, N.-Z.; Zeng, G.-L.; Yang, M.; Zuo, G.-Q.; Gan, X.-N.; Ren, H.; Tang, K.-F. Down-regulation of Dicer in hepatocellular carcinoma. Med. Oncol. 2010, 28, 804–809. [Google Scholar] [CrossRef] [PubMed]
  32. Karube, Y.; Tanaka, H.; Osada, H.; Tomida, S.; Tatematsu, Y.; Yanagisawa, K.; Yatabe, Y.; Takamizawa, J.; Miyoshi, S.; Mitsudomi, T.; et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96, 111–115. [Google Scholar] [CrossRef] [PubMed]
  33. Schultz, K.A.P.; Stewart, D.R.; Kamihara, J.; Bauer, A.J.; Merideth, M.A.; Stratton, P.; Huryn, L.A.; Harris, A.K.; Doros, L.; Field, A.; et al. DICER1 Tumor Predisposition. In GeneReviews®; Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993–2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK196157/ (accessed on 4 August 2024).
  34. Robertson, J.C.; Jorcyk, C.L.; Oxford, J.T. DICER1 Syndrome: DICER1 Mutations in Rare Cancers. Cancers 2018, 10, 143. [Google Scholar] [CrossRef] [PubMed]
  35. Hill, D.A.; Ivanovich, J.; Priest, J.R.; Gurnett, C.A.; Dehner, L.P.; Desruisseau, D.; Jarzembowski, J.A.; Wikenheiser-Brokamp, K.A.; Suarez, B.K.; Whelan, A.J.; et al. DICER1 Mutations in Familial Pleuropulmonary Blastoma. Science 2009, 325, 965. [Google Scholar] [CrossRef]
  36. de Kock, L.; Wang, Y.C.; Revil, T.; Badescu, D.; Rivera, B.; Sabbaghian, N.; Wu, M.; Weber, E.; Sandoval, C.; Hopman, S.M.J.; et al. High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1 syndrome. J. Med. Genet. 2016, 53, 43–52. [Google Scholar] [CrossRef]
  37. Ricarte-Filho, J.C.; Casado-Medrano, V.; Reichenberger, E.; Spangler, Z.; Scheerer, M.; Isaza, A.; Baran, J.; Patel, T.; MacFarland, S.P.; Brodeur, G.M.; et al. DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer. Front. Endocrinol. 2023, 14, 1083382. [Google Scholar] [CrossRef] [PubMed]
  38. Dobrijević, Z.; Matijašević, S.; Denčić, T.I.; Savić-Pavićević, D.; Nedić, O.; Brajušković, G. Association between genetic variants in DICER1 and cancer risk: An updated meta-analysis. Gene 2020, 766, 145132. [Google Scholar] [CrossRef]
  39. Borghini, A.; Pulignani, S.; Mercuri, A.; Vecoli, C.; Turchi, S.; Carpeggiani, C.; Andreassi, M.G. Influence of genetic polymorphisms in DICER and XPO5 genes on the risk of coronary artery disease and circulating levels of vascular miRNAs. Thromb. Res. 2019, 180, 32–36. [Google Scholar] [CrossRef] [PubMed]
  40. Saeki, M.; Watanabe, M.; Inoue, N.; Tokiyoshi, E.; Takuse, Y.; Arakawa, Y.; Hidaka, Y.; Iwatani, Y. DICER and DROSHA gene expression and polymorphisms in autoimmune thyroid diseases. Autoimmunity 2016, 49, 514–522. [Google Scholar] [CrossRef]
  41. Zhou, Y.; Wang, J.; Lu, X.; Song, X.; Ye, Y.; Zhou, J.; Ying, B.; Wang, L. Evaluation of Six SNPs of MicroRNA Machinery Genes and Risk of Schizophrenia. J. Mol. Neurosci. 2013, 49, 594–599. [Google Scholar] [CrossRef]
  42. Huang, X.; An, Y.; Li, X.; Wang, D.; Tan, H.; Lei, J. Genetic variants in DICER1, DROSHA, RAN, and XPO5 genes and risk of pregnancy-induced hypertension. Pregnancy Hypertens. 2019, 16, 161–166. [Google Scholar] [CrossRef] [PubMed]
  43. Moghbelinejad, S.; Najafipour, R.; Momeni, A. Association of rs1057035polymorphism in microRNA biogenesis pathway gene (DICER1) with azoospermia among Iranian population. Genes Genom. 2018, 40, 17–24. [Google Scholar] [CrossRef]
  44. Na Kim, M.; Kim, J.O.; Lee, S.M.; Park, H.; Lee, J.H.; Rim, K.S.; Hwang, S.G.; Kim, N.K. Variation in the Dicer and RAN Genes Are Associated with Survival in Patients with Hepatocellular Carcinoma. PLoS ONE 2016, 11, e0162279. [Google Scholar] [CrossRef]
  45. Osuch-Wojcikiewicz, E.; Bruzgielewicz, A.; Niemczyk, K.; Sieniawska-Buccella, O.; Nowak, A.; Walczak, A.; Majsterek, I. Association of Polymorphic Variants of miRNA Processing Genes with Larynx Cancer Risk in a Polish Population. BioMed. Res. Int. 2015, 2015, 298378. [Google Scholar] [CrossRef] [PubMed]
  46. Dong, J.; Wang, J.; Shan, C.; Zhang, H.; Xu, O. MicroRNA-892a regulates laryngocarcinoma cell proliferation via Dicer. Exp. Biol. Med. 2020, 245, 1222–1232. [Google Scholar] [CrossRef]
  47. Borg, R.; Cauchi, R.J. GEMINs: Potential therapeutic targets for spinal muscular atrophy? Front. Neurosci. 2014, 8, 325. [Google Scholar] [CrossRef]
  48. Aldhalaan, H.; AlBakheet, A.; AlRuways, S.; AlMutairi, N.; AlNakiyah, M.; AlGhofaili, R.; Cardona-Londoño, K.J.; Alahmadi, K.O.; AlQudairy, H.; AlRasheed, M.M.; et al. A Novel GEMIN4 Variant in a Consanguineous Family Leads to Neurodevelopmental Impairment with Severe Microcephaly, Spastic Quadriplegia, Epilepsy, and Cataracts. Genes 2021, 13, 92. [Google Scholar] [CrossRef]
  49. Altassan, R.; Qudair, A.; Alokaili, R.; Alhasan, K.; Faqeih, E.A.; Alhashem, A.; Alowain, M.; Alsayed, M.; Rahbeeni, Z.; Albadi, L.; et al. Further delineation of GEMIN4 related neurodevelopmental disorder with microcephaly, cataract, and renal abnormalities syndrome. Am. J. Med. Genet. Part A 2022, 188, 2932–2940. [Google Scholar] [CrossRef]
  50. Patel, N.; Anand, D.; Monies, D.; Maddirevula, S.; Khan, A.O.; Algoufi, T.; Alowain, M.; Faqeih, E.; Alshammari, M.; Qudair, A.; et al. Novel phenotypes and loci identified through clinical genomics approaches to pediatric cataract. Hum. Genet. 2017, 136, 205–225. [Google Scholar] [CrossRef]
  51. Song, X.; Zhong, H.; Wu, Q.; Wang, M.; Zhou, J.; Zhou, Y.; Lu, X.; Ying, B. Association between SNPs in microRNA machinery genes and gastric cancer susceptibility, invasion, and metastasis in Chinese Han population. Oncotarget 2017, 8, 86435. [Google Scholar] [CrossRef]
  52. Fang, X.; Yin, Z.; Li, X.; Xia, L.; Zhou, B. Polymorphisms in GEMIN4 and AGO1 Genes Are Associated with the Risk of Lung Cancer: A Case-Control Study in Chinese Female Non-Smokers. Int. J. Environ. Res. Public Health 2016, 13, 939. [Google Scholar] [CrossRef]
  53. Lin, J.; Horikawa, Y.; Tamboli, P.; Clague, J.; Wood, C.G.; Wu, X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010, 31, 1805–1812. [Google Scholar] [CrossRef]
  54. Cheng, H.; Li, H.; Feng, Y.; Zhang, Z. Correlation analysis between SNPs in microRNA-machinery genes and tuberculosis susceptibility in the Chinese Uygur population. Medicine 2018, 97, e13637. [Google Scholar] [CrossRef]
  55. Liu, J.; Liu, J.; Wei, M.; He, Y.; Liao, B.; Liao, G.; Li, H.; Huang, J. Genetic Variants in the MicroRNA Machinery Gene GEMIN4 Are Associated with Risk of Prostate Cancer: A Case-control Study of the Chinese Han Population. DNA Cell Biol. 2012, 31, 1296–1302. [Google Scholar] [CrossRef]
  56. Yang, P.-W.; Huang, Y.-C.; Hsieh, C.-Y.; Hua, K.-T.; Huang, Y.-T.; Chiang, T.-H.; Chen, J.-S.; Huang, P.-M.; Hsu, H.-H.; Kuo, S.-W.; et al. Association of miRNA-related Genetic Polymorphisms and Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Ann. Surg. Oncol. 2014, 21, 601–609. [Google Scholar] [CrossRef]
Table 1. Demographic and clinical characteristics of CML patients and healthy individuals.
Table 1. Demographic and clinical characteristics of CML patients and healthy individuals.
CML
n = 296 (%)		Controls
n = 485 (%)
Age, median ± SD45 ± 14.7 48 ± 7.4
Males170 (57%)271 (56%)
Females126 (43%)214 (44%)
Sokal Score (n = 118)
HR52 (44%)-
IR34 (29%)-
LR32 (27%)-
Hasford Score (n = 118)
HR48 (41%)-
IR36 (30%)-
LR34 (29%)-
EUTOS Score (n = 97)
HR50 (52%)-
LR47 (48%)-
SD: standard deviation, CML: chronic myeloid leukemia, HR: high risk, IR: intermediate risk, and LR: low risk.
Table 2. Allelic associations of SNVs in miRNA machinery genes with CML.
Table 2. Allelic associations of SNVs in miRNA machinery genes with CML.
GeneSNVAllelesCases
Freq (n)		Controls
Freq (n)		p-ValueOR (CI 95%)
GEMIN3rs197388A0.92 (538)0.91 (878)
T0.08 (46)0.09 (84)0.5570.89 (0.614–1.301)
DROSHArs10719G0.67 (396)0.65 (628)
A0.33 (196)0.35 (342)0.3850.91 (0.732–1.128)
rs6877842G0.90 (535)0.90 (874)
C0.10 (57)0.10 (96)0.8620.97 (0.687–1.370)
XPO5rs11077T0.61 (358)0.63 (614)
G0.39 (232)0.37 (356)0.3001.12 (0.905–1.382)
rs34324334C0.94 (556)0.93 (906)
T0.06 (36)0.07 (64)0.6850.92 (0.601–1.397)
AGO2rs2293939G0.78 (463)0.79 (764)
A0.22 (129)0.21 (204)0.7371.04 (0.813–1.338)
rs4961280C0.67 (397)0.63 (607)
A0.33 (193)0.37 (363)0.0590.81 (0.655–1.009)
DICERrs3742330A0.83 (492)0.82 (797)
G0.17 (98)0.18 (173)0.5350.92 (0.699–1.205)
rs13078T0.91 (539)0.94 (915)
A0.09 (53)0.06 (55)0.0131.64 (1.105–2.421)
GEMIN4rs7813A0.70 (414)0.71 (685)
G0.30 (178)0.29 (285)0.7731.03 (0.826–1.292)
rs2740349T0.81 (477)0.80 (776)
C0.19 (115)0.20 (194)0.7820.96 (0.745–1.247)
DGCR8rs720012G0.57 (334)0.55 (533)
A0.43 (256)0.45 (437)0.5210.93 (0.760–1.149)
TNRC6Brs9611280G0.98 (578)0.97 (937)
A0.02 (14)0.03 (33)0.2440.69 (0.364–1.296)
Bold letters indicate significant associations.
Table 3. Genotypic association of SNVs in miRNA machinery genes with CML.
Table 3. Genotypic association of SNVs in miRNA machinery genes with CML.
GeneSNVAllelesGenotypeCases
Freq (n)		Controls
Freq (n)		p-ValueOR (CI 95%)
GEMIN3rs197388A/TAA0.86 (250)0.84 (404)
AT0.13 (38)0.15 (70)0.5460.88 (0.569–1.339)
TT0.01 (4)0.01 (7)1.000.94 (0.235–3.220)
DROSHArs10719G/AGG0.45 (134)0.43 (208)
GA0.43 (128)0.44 (212)0.6800.94 (0.688–1.277)
AA0.12 (34)0.13 (65)0.3830.81 (0.505–1.294)
rs6877842G/CGG0.811 (240)0.82 (396)
GC0.186 (55)0.17 (82)0.5981.11 (0.756–1.612)
CC0.003 (1)0.01 (7)0.2690.26 (0.010–1.540)
XPO5rs11077T/GTT0.37 (108)0.41 (197)
TG0.48 (142)0.45 (220)0.3101.18 (0.859–1.616)
GG0.15 (45)0.14 (68)0.4061.21 (0.771–1.880)
rs34324334C/TCC0.89 (263)0.87 (424)
CT0.10 (30)0.12 (58)0.4450.84 (0.518–1.326)
TT0.01 (3)0.01 (3)0.6801.61 (0.276–9.437)
AGO2rs2293939G/AGG0.62 (183)0.62 (301)
GA0.33 (97)0.34 (162)0.9240.99 (0.720–1.344)
AA0.05 (16)0.04 (21)0.5121.26 (0.627–2.470)
rs4961280C/ACC0.47 (138)0.40 (193)
CA0.41 (121)0.45 (221)0.09250.77 (0.561–1.046)
AA0.12 (36)0.15 (71)0.1390.71 (0.446–1.117)
DICER1rs3742330A/GAA0.69 (205)0.68 (329)
AG0.28 (82)0.29 (139)0.7410.95 (0.683–1.308)
GG0.03 (8)0.03 (17)0.5200.76 (0.303–1.763)
rs13078T/ATT0.855 (253)0.889 (431)
TA0.111 (33)0.109 (53)0.8021.06 (0.663–1.679)
AA0.034 (10)0.002 (1)0.000415.06 (2.824–373.6)
GEMIN4rs7813A/GAA0.51 (150)0.50 (244)
AG0.38 (114)0.41 (197)0.700.94 (0.691–1.280)
GG0.11 (32)0.09 (44)0.5091.18 (0.713–1.947)
rs2740349T/CTT0.66 (196)0.65 (313)
TC0.29 (85)0.31 (150)0.5410.91 (0.656–1.246)
CC0.05 (15)0.04 (22)0.8061.09 (0.540–2.150)
DGCR8rs720012G/AGG0.33 (97)0.31 (149)
GA0.47 (140)0.48 (235)0.5990.92 (0.658–1.275)
AA0.20 (58)0.21 (101)0.5510.88 (0.583–1.332)
TNRC6Brs9611280G/AGG0.95 (282)0.93 (452)
GA0.05 (14)0.07 (33)0.2370.68 (0.348–1.280)
AA0 (0)0 (0)NANA
Bold letters indicate significant associations.
Table 4. Variants in components of miRNA biosynthesis process and CML prognosis.
Table 4. Variants in components of miRNA biosynthesis process and CML prognosis.
Gene/SNVAlleleSokalHasfordEutos
HR
n = 52		LR-IR
n = 66		ORHR
n = 48		LR-IR
n = 70		ORHR
n = 50		LR
n = 47		OR
GEMIN3
rs197388		 
T		 
0.08		 
0.05		 
1.83		 
0.07		 
0.04		 
1.77		 
0.08		 
0.04		 
2.00
DROSHA
rs10719
rs6877842
A0.280.360.70.270.340.710.280.360.68
C0.120.081.440.110.091.380.100.091.07
XPO5
rs11077
rs34324334
G0.440.361.390.470.361.540.420.421.01
T0.060.031.960.040.040.970.050.050.96
AGO2
rs2293939
rs4961280
A0.20.21.030.210.191.100.210.181.24
A0.370.331.150.330.370.850.340.400.79
DICER1
rs3742330
rs13078
G0.130.170.780.150.160.920.160.170.95
A0.080.110.70.090.091.010.090.090.96
GEMIN4
rs7813
rs2740349
G0.360.261.590.390.241.96 *0.350.261.53
C0.250.171.670.270.142.23 **0.230.171.49
DGCR8
rs720012		 
A		 
0.6		 
0.56		 
1.16		 
0.59		 
0.55		 
1.20		 
0.58		 
0.56		 
1.07
TNRC6B
rs9611280		 
A		 
0.02		 
0.02		 
0.84		 
0.03		 
0.01		 
2.23		 
0.02		 
0.02		 
0.96
Bold letters indicate significant associations. * p-value 0.019; CI 95% (1.11–3.44); ** p-value 0.015; CI 95% (1.16–4.28). HR: high risk, IR: intermediate risk, and LR: low risk.
Table 5. Linear regression estimating age at diagnosis in years.
Table 5. Linear regression estimating age at diagnosis in years.
GeneSNVMinor Allelep-ValueβCI 95%
GEMIN3rs197388T0.705−1.077(−6.64–4.48)
DROSHArs10719A0.544−0.9741(−4.11–2.16)
rs6877842C0.9260.2497(−5.02–5.52)
XPO5rs11077G0.306−1.564(−4.55–1.42)
rs34324334T0.557−1.841(−7.97–4.29)
AGO2rs2293939A0.6780.788(−2.93–4.51)
rs4961280A0.781−0.4242(−3.41–2.56)
DICER1rs3742330G0.460−1.554(−5.67–2.56)
rs13078A0.1623.106(−1.23–7.45)
GEMIN4rs7813G0.0592.955(−0.09–6.00)
rs2740349C0.0035.395(1.88–8.91)
DGCR8rs720012A0.296−1.589(−4.56–1.38)
TNRC6Brs9611280A0.3015.233(−4.66–15.12)
Bold letters indicate significant associations. β-value: age of diagnosis in years.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chavaro-Francisco, G.; Hernández-Zavala, A.; Bravo-Cidro, C.E.; Rios-Rodriguez, S.; Muciño-Sánchez, M.; López-López, M.; Castro-Martínez, X.H.; Olarte-Carrillo, I.; Garcia-Laguna, A.; Barranco-Lampón, G.; et al. Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia. Genes 2024, 15, 1054. https://doi.org/10.3390/genes15081054

AMA Style

Chavaro-Francisco G, Hernández-Zavala A, Bravo-Cidro CE, Rios-Rodriguez S, Muciño-Sánchez M, López-López M, Castro-Martínez XH, Olarte-Carrillo I, Garcia-Laguna A, Barranco-Lampón G, et al. Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia. Genes. 2024; 15(8):1054. https://doi.org/10.3390/genes15081054

Chicago/Turabian Style

Chavaro-Francisco, Guillermina, Araceli Hernández-Zavala, Camila E. Bravo-Cidro, Sandybel Rios-Rodriguez, Mabel Muciño-Sánchez, Marisol López-López, Xóchitl H. Castro-Martínez, Irma Olarte-Carrillo, Anel Garcia-Laguna, Gilberto Barranco-Lampón, and et al. 2024. "Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia" Genes 15, no. 8: 1054. https://doi.org/10.3390/genes15081054

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop